Skip to main content

Advertisement

Table 1 Baseline data by group

From: Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4–5: a retrospective single center study

  Already in VDRA treatment (aVDRA) Starting VDRA treatment (VDRA+) No VDRA treatment (VDRA-) P
N 35 59 52  
Age (mean, range) 59,4 (19–89) 57,2 (19–86) 65,1 (34–95)* P < 0.05
Sex (% male) 71 71 63 Ns
Diagnosis
Glomerulonephritis (n) 6 14 9  
Tubulointerstitiel nephritis (n) 1 1 1  
Pyeolonephritis (n) 1 0 1  
Obstructive nephropathy (n) 3 5 3  
Polycystic (ADPKD) (n) 0 5 4  
Hypertensive (n) 2 6 3  
DM type I (n) 0 7 4  
DM type II (n) 6 4 10  
Unknown (n) 13 11 13  
Other (n) 3 6 4  
Observation time (days)
Total 17490 44282 30157 P < 0.05
Median (range) 500 (67–1603) 751(84–1716) 580 (93–1487) P < 0.05
Kidney Function
eGFR (ml/min/1.73 m2) 14.8 ± 5.8 16.5 ± 4.3 18.8 ± 10.9 Ns
Creatinine Clearance (ml/min) 19.2 ± 6.5 21.7 ± 15.6 23.8 ± 15.8 Ns
U-Albumin (g/24 h) 1.55 ± 1.96 1.96 ± 1.97 2.41 ± 2.32 Ns
Mineral-Bone
S-calcium (mmol/l) 1.12 ± 0.11* 1.17 ± 0.07 1.21 ± 0.08 P < 0.001
S-phosphate (mmol/l) 1.67 ± 0.50* 1.45 ± 0.32 1.40 ± 0.32 P < 0.005
S-PTH (pmol/l)* 24.0 ± 16.0 21.3 ± 10.6 14.9 ± 10.1* P < 0.005
Blood pressure
Systolic (mmHg) 147 ± 19 151 ± 20 156 ± 20 Ns
Diastolic (mmHg) 85 ± 13 85 ± 11 82 ± 11 Ns
Medication
Alfacalcidol (μg/week) 3.0 ± 1.7    
Calcium with Vitamin D (n,(%)) 6 (17%) 4 (7%) 12 (23%) Ns
Phosphate-binder (n,(%)) 9 (25%)* 7 (12%) 7 (13%) P < 0.01
ACEi/ARB (n,(%)) 21(60%)1 dual 36 (61%)6 dual 24 (46%) 3 dual Ns
  1. Included are adult patients with at least one 24 h urine with albuminuria > 0.3 g/d. Mean ± SD if not otherwise stated. * This group differed significantly from the other two.